Skip to main content

Advertisement

Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

Fig. 5

AZD9291 continuously blocks the activation of EGFR/ERK pathway in GBM cells. a and b U87 and U251 cells were exposed to indicated concentrations of AZD9291 for 24 h and then stimulated with EGF (100 ng/mL) for 30 min. Cell lysates were prepared and examined using Western blot analysis with indicated antibodies. c and d U87 and U251 cells were treated with AZD9291 or Erlotinib for 4, 24 and 48 h. The expression level of p-ERK were assessed using Western blot analysis

Back to article page